Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Regulatory overview and development of business model for autologous T cell cancer treatment

Reference number
Coordinator TCER AB - Center for Molecular Medicine
Funding from Vinnova SEK 300 000
Project duration October 2017 - February 2018
Status Completed
Venture Innovative Startups

Important results from the project

We have developed a new concept called A-STAR, for generation of next-generation biologics, based on T-cells. The purpose of the present project was to map the regulatory framework of our medical procedure and develop a suitable business model

Expected long term effects

We have developed a regulatory road map for our product. In addition, we have established the basis for a business model for personalized T-cell transfusion in the treatment of cancer. Understanding of the regulatory landscape and development of business models are crucial activities that will govern future funding needed to reach the market.

Approach and implementation

TCER AB is based on more than 20 years of research. The work of mapping the regulatory framework has been carried out together with world-leading clinical immunologists in close cooperation with the CRO Scandinavian Development System. Establishing a credible business plan and economic analysis has been done in cooperation with an external international highly experienced business developer.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 1 March 2019

Reference number 2017-04186

Page statistics